Literature DB >> 29975048

Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.

Xiaoqing Feng1,2, Huanchen Wang2,3, Mengchun Ye2,4, Xue-Tao Xu4, Ying Xu5, Wenzhe Yang2, Han-Ting Zhang5, Guoqiang Song1, Hengming Ke2.   

Abstract

Inhibitors of phosphodiesterases (PDEs) have been widely studied as therapeutics for the treatment of human diseases, but improvement of inhibitor selectivity is still desirable for the enhancement of inhibitor potency. Here, we report identification of a water-containing subpocket as a PDE4-specific pocket for inhibitor binding. We designed against the pocket and synthesized two enantiomers of PDE4 inhibitor Zl-n-91. The ( S)-Zl-n-91 enantiomer showed IC50 values of 12 and 20 nM for the catalytic domains of PDE4D2 and PDE4B2B, respectively, selectivity several thousand-fold greater than those of other PDE families, and potent neuroprotection activities. Crystal structures of the PDE4D2 catalytic domain in complex with each Zl-n-91 enantiomer revealed that ( S)-Zl-n-91 but not ( R)-Zl-n-91 formed a hydrogen bond with the bound water in the pocket, thus explaining its higher affinity. The structural superposition between the PDE families revealed that this water-containing subpocket is unique to PDE4 and thus valuable for the design of PDE4 selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29975048      PMCID: PMC6088244          DOI: 10.1021/acs.biochem.8b00336

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  49 in total

1.  Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Authors:  Nathalie Chauret; Daniel Guay; Chun Li; Stephen Day; José Silva; Marc Blouin; Yves Ducharme; James A Yergey; Deborah A Nicoll-Griffith
Journal:  Bioorg Med Chem Lett       Date:  2002-08-19       Impact factor: 2.823

2.  Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.

Authors:  Peng Li; Hailin Zheng; Jun Zhao; Lei Zhang; Wei Yao; Hongwen Zhu; J David Beard; Koh Ida; Weston Lane; Gyorgy Snell; Satoshi Sogabe; Charles J Heyser; Gretchen L Snyder; Joseph P Hendrick; Kimberly E Vanover; Robert E Davis; Lawrence P Wennogle
Journal:  J Med Chem       Date:  2016-02-02       Impact factor: 7.446

Review 3.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 4.  Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Authors:  Nathan A Pinner; Leslie A Hamilton; Anthony Hughes
Journal:  Clin Ther       Date:  2012-01       Impact factor: 3.393

Review 5.  AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.

Authors:  Rachel Nazarian; Jeffrey M Weinberg
Journal:  Curr Opin Investig Drugs       Date:  2009-11

6.  Structural insight into substrate specificity of phosphodiesterase 10.

Authors:  Huanchen Wang; Yudong Liu; Jing Hou; Meiyan Zheng; Howard Robinson; Hengming Ke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

Review 7.  Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.

Authors:  Jusleen Ahluwalia; Jeremy Udkoff; Andrea Waldman; Jenna Borok; Lawrence F Eichenfield
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Authors:  Patrick R Verhoest; Douglas S Chapin; Michael Corman; Kari Fonseca; John F Harms; Xinjun Hou; Eric S Marr; Frank S Menniti; Frederick Nelson; Rebecca O'Connor; Jayvardhan Pandit; Caroline Proulx-Lafrance; Anne W Schmidt; Christopher J Schmidt; Judith A Suiciak; Spiros Liras
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 10.  Phosphodiesterase 4-targeted treatments for autoimmune diseases.

Authors:  Neal Kumar; Ari M Goldminz; Noori Kim; Alice B Gottlieb
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more
  3 in total

1.  DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.

Authors:  David W C Hunt; Iordanka A Ivanova; Lina Dagnino
Journal:  Tissue Barriers       Date:  2020-06-01

2.  ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer.

Authors:  Longming Liang; Hansi Chen; Ping Mao; Yuyu Li; Lijun Xu; Yujie He; Yunping Mu; Allan Z Zhao; Sujin Zhou; Zhenggang Zhao; Fanghong Li
Journal:  Invest New Drugs       Date:  2022-06-08       Impact factor: 3.651

3.  Identification of a Selective PDE4B Inhibitor From Bryophyllum pinnatum by Target Fishing Study and In Vitro Evaluation of Quercetin 3-O-α-L-Arabinopyranosyl-(1→2)-O-α-L-Rhamnopyranoside.

Authors:  Estela M G Lourenço; Júlia M Fernandes; Vinícius de F Carvalho; Raphael Grougnet; Marco A Martins; Alessandro K Jordão; Silvana M Zucolotto; Euzébio G Barbosa
Journal:  Front Pharmacol       Date:  2020-01-22       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.